Literature DB >> 6845401

Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion.

G Houin, A Beucler, S Richelet, R Brioude, C Lafaix, J P Tillement.   

Abstract

Four rates of rifampicin infusion ranging from 3.3 to 15 mg/min in 12 tuberculous patients were studied. Blood samples (n = 10) were drawn during infusion and 8 h later. Urine samples were collected in six fractions during a 24-h period. Rifampicin and desacetylrifampicin were measured by high-pressure liquid chromatography. Results show that the maximum plasma concentrations increase linearly for each dose with the rate of infusion, and that the amounts excreted in the urines are highly dependent on the administered dose. Simulation of plasma concentrations after different dosage regimens shows that a double rate of infusion--20 mg min-1 during 1 h and then 200 mg h-1--allows plasma concentrations to be quickly reached and maintained at a 20 mg L-1 level, far higher than the minimum inhibitory concentrations of most germs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6845401     DOI: 10.1097/00007691-198303000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

2.  Isoniazid and rifampicin inhibit allosterically heme binding to albumin and peroxynitrite isomerization by heme-albumin.

Authors:  Paolo Ascenzi; Alessandro Bolli; Alessandra di Masi; Grazia R Tundo; Gabriella Fanali; Massimo Coletta; Mauro Fasano
Journal:  J Biol Inorg Chem       Date:  2010-09-25       Impact factor: 3.358

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

5.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

7.  Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Authors:  Rovina Ruslami; Hanneke M J Nijland; I Gusti N Adhiarta; Sri H K S Kariadi; Bachti Alisjahbana; Rob E Aarnoutse; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

8.  Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations.

Authors:  Christoph Thiel; Ines Smit; Vanessa Baier; Henrik Cordes; Brigida Fabry; Lars Mathias Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-08-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.